MyFinsight
Home
Blog
About
Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (ABUS)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$4,535K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Disposition of investments in ma...
Issuance of common shares pursua...
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Purchase of investments in marke...
Net income (loss)
Accounts payable and accrued lia...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
-5,143
169,695
-3,756
-7,742
Depreciation and amortization
-
-
363
-
Depreciation
11
-341
-
11
Loss on impairment of leasehold improvements and lab equipment
0
0
0
0
Gain on sale of property and equipment
-
-
674
-
Stock-based compensation expense
1,625
1,359
1,262
1,263
Change in fair value of contingent consideration
213
209
-2,657
268
Non-cash royalty revenue
180
181
259
249
Non-cash interest expense
13
17
17
23
Net accretion and amortization of investments in marketable securities
321
354
422
541
Accounts receivable
82
-1,160
129
-120
Increase (decrease) in accounts and other receivables
632
178,741
-
-
Prepaid expenses and other assets
-215
195
-1,298
-1,040
Accounts payable and accrued liabilities
-1,624
-985
806
145
Change in deferred license revenue
0
0
0
0
Other liabilities
-113
-105
-177
-155
Net cash used in operating activities
-6,018
-8,110
-4,680
-5,817
Purchase of investments in marketable securities
23,662
13,800
25,547
51,300
Proceeds from sale of property and equipment
0
-
355
0
Disposition of investments in marketable securities
22,000
16,000
23,831
41,281
Acquisition of property and equipment
-
-
0
0
Net cash provided by investing activities
-1,661
2,199
-1,361
-10,019
Issuance of common shares pursuant to the open market sale agreement
-
-
0
0
Issuance of common shares pursuant to exercise of stock options
3,148
11,531
1,640
794
Issuance of common shares pursuant to espp
0
88
0
50
Net cash provided by financing activities
3,148
11,619
1,640
844
Effect of foreign exchange rate changes on cash and cash equivalents
-4
-10
1
-12
Increase in cash and cash equivalents
-4,535
5,698
-4,400
-15,004
Cash and cash equivalents, beginning of period
23,706
18,008
22,408
36,330
Cash and cash equivalents, end of period
19,171
23,706
18,008
22,408
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Issuance of common shares
pursuant to exercise of...
$3,148K
(1.35%↑ Y/Y)
Net cash provided by
financing activities
$3,148K
(-2.75%↓ Y/Y)
Increase in cash and cash
equivalents
-$4,535K
(-519.13%↓ Y/Y)
Canceled cashflow
$3,148K
Stock-based compensation
expense
$1,625K
(-63.30%↓ Y/Y)
Prepaid expenses and
other assets
-$215K
(-133.59%↓ Y/Y)
Change in fair value of
contingent consideration
$213K
(-61.90%↓ Y/Y)
Non-cash interest
expense
$13K
(-76.36%↓ Y/Y)
Depreciation
$11K
(-96.77%↓ Y/Y)
Disposition of investments
in marketable...
$22,000K
(-75.60%↓ Y/Y)
Net cash used in
operating activities
-$6,018K
(79.35%↑ Y/Y)
Canceled cashflow
$2,077K
Net cash provided by
investing activities
-$1,661K
(-106.16%↓ Y/Y)
Effect of foreign
exchange rate changes on...
-$4K
(-116.00%↓ Y/Y)
Canceled cashflow
$22,000K
Net income (loss)
-$5,143K
(76.63%↑ Y/Y)
Accounts payable and
accrued liabilities
-$1,624K
(46.86%↑ Y/Y)
Increase (decrease) in
accounts and other...
$632K
Net accretion and
amortization of investments...
$321K
(-76.84%↓ Y/Y)
Non-cash royalty revenue
$180K
(-81.52%↓ Y/Y)
Other liabilities
-$113K
(49.78%↑ Y/Y)
Accounts receivable
$82K
(105.92%↑ Y/Y)
Purchase of investments
in marketable...
$23,662K
(-62.57%↓ Y/Y)
Buy us a coffee